GleamWall
中文EN

MBOT Microbot Medical Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 883975 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-42.3%
TTM EPS YoY40.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-26.3%
ROA-24.8%
ROIC (approx.)-25.2%
Asset turnover—

Leverage & solvency

Liabilities / assets7.0%
Debt / equity0.00x
Current ratio15.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio0.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$72,000$241,000$105,000—————
Cost of revenue$1.09M$884,000$103,000—————
Gross profit-$1.02M-$643,000$2,000—————
R&D expense$1.63M$1.86M$1.29M$1.54M$1.17M$2.11M$1.46M$1.98M
SG&A expense$1.84M$3.68M$3.03M$2.60M$2.16M$1.61M$1.56M$1.45M
Operating income-$6.49M-$6.19M-$4.32M-$4.14M-$3.86M-$3.72M-$3.02M-$3.43M
Net income-$5.84M-$5.63M-$3.67M-$3.46M-$3.58M-$3.50M-$2.60M-$3.39M
EBITDA-$6.47M-$6.17M-$4.31M-$4.13M-$3.85M-$3.71M-$3.01M-$3.40M
EPS (basic)-0.09-0.08-0.05—-0.07-0.10-0.08—
EPS (diluted)-0.09-0.08-0.05—-0.07-0.10-0.08—
Weighted avg. shares (diluted)67.16M67.16M67.16M—48.10M36.49M31.09M—
Balance sheet
Cash & equivalents$2.29M$3.15M$3.66M$3.91M$6.70M$4.08M$3.22M$3.11M
Short-term investments$59.54M$64.22M$68.84M$74.68M$73.45M$28.59M$27.17M$2.36M
Receivables$90,000$176,000$105,000—————
Inventory$3.21M$2.91M$2.26M$584,000————
Current assets$66.87M$72.17M$76.53M$79.82M$80.78M$32.89M$30.66M$5.82M
PP&E, net$486,000$316,000$188,000$93,000$78,000$75,000$78,000$80,000
Total assets$68.21M$73.36M$78.07M$81.54M$81.76M$33.13M$30.89M$6.03M
Current liabilities$4.26M$3.89M$3.39M$3.42M$2.93M$2.73M$1.89M$2.46M
Total liabilities$4.76M$4.44M$3.96M$3.99M$3.54M$2.77M$1.94M$2.50M
Shareholders' equity$63.45M$68.93M$74.11M$77.55M$78.22M$30.36M$28.95M$3.53M
Shares outstanding67.16M67.16M67.16M67.16M65.83M37.96M34.74M19.40M
Cash flow statement
Operating cash flow-$5.41M-$4.99M-$5.05M-$3.76M-$3.84M-$2.57M-$2.87M-$1.69M
Capital expenditure$115,000$142,000$108,000$25,000$13,000$9,000$13,000$7,000
Free cash flow-$5.52M-$5.13M-$5.16M-$3.78M-$3.85M-$2.58M-$2.89M-$1.70M
Investing cash flow$4.55M$4.47M$5.00M-$1.53M-$44.71M-$1.31M-$24.83M$1.50M
Financing cash flow$0——$2.51M$51.18M$4.75M$27.81M$2.83M
Depreciation & amortization$28,000$15,000$12,000$10,000$10,000$12,000$15,000$26,000
Stock-based compensation$362,000$433,000$222,000$236,000$328,000$237,000$256,000$282,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.